Bayer bets $1.5B that Vividion will help it target the 'undruggable' and make 1+1=3

Sometimes, it takes $1.5 billion to make "one plus one equal three."

Bayer wanted to "really transform" its R&D engine under its recently installed pharma R&D leader. Meanwhile, the public markets had nothing on an acquisition deal for Vividion Therapeutics, so the biotech scrapped its IPO vision.